About this trial
Acute bronchiolitis is a common disease in children under the age of two, caused mainly by the respiratory syncytial virus (RSV). Furthermore, given the same medical history, it is still very difficult to predict the course and severity of the infection at the onset of symptoms, Some studies have highlighted the importance of the microbiota (intestinal, oral or nasopharyngeal) and of the immune response to RSV in children, We will include 80 children under 2 years old with hospitalized bronchiolitis and non-hospitalized bronchiolitis. Oral, nasal and stool samples will be taken to study the various microbiota in search of dysbiosis. A capillary blood sample will be taken for immune studies.
Eligibility criteria
Qualifiers
Infants <12 months
With bronchiolitis during RSV epidemic season
No chronic illness
No bronchiolitis medical history
Disqualifiers
Chronic respiratory illness
Medical history of bronchiolitis or newborn asthma
Treatment with immunosuppressants
Patient with no social security affiliation
Trial design
Treatments tested in this trial
- Sampling
Treatment groups
Sponsors and collaborators
Assistance Publique - Hôpitaux de Paris
Lead sponsor
Infectious Diseases Models for Innovative Therapies center
Collaborator